Lamb Weston names Michael Smith as CEO-February 2024-www.financetom.com

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Lamb Weston names Michael Smith as CEO

Dec 19, 2024 3:32 AM

Dec 19 (Reuters) - Lamb Weston ( LW ) on Thursday named

Michael Smith as its chief executive officer as the frozen

potato products maker faces activist investor pressure to make

changes to its top brass or sell itself.

(Reporting by Juveria Tabassum in Bengaluru; Editing by Abinaya

Vijayaraghavan)

Previous page： Tower Semiconductor Q3 Adjusted Earnings Fall, Revenue Rises; Q4 Revenue Guidance Issued Next page： Starwood Property Q3 revenue beats estimates

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Tower Semiconductor Q3 Adjusted Earnings Fall, Revenue Rises; Q4 Revenue Guidance Issued

Nov 10, 2025

07:19 AM EST, 11/10/2025 (MT Newswires) -- Tower Semiconductor ( TSEM ) reported Q3 adjusted earnings Monday of $0.55 per diluted share, down from $0.57 a year earlier. Analysts polled by FactSet expected $0.54. Revenue for the quarter ended Sept. 30 was $395.7 million, up from $370.5 million a year earlier. Analysts surveyed by FactSet expected $395 million. The company...

Starwood Property Q3 revenue beats estimates

Nov 10, 2025

Overview * Starwood Q3 revenue beats analyst expectations, adjusted net income misses estimates * Company invested $4.6 bln in Q3, including $2.2 bln in triple net lease investments * Raised $2.3 bln of capital across equity, term loan B, and high yield markets Outlook * Company did not provide specific guidance for future quarters or full year Result Drivers *...

Autoimmune drugmaker Immunovant's Q2 net loss misses estimates

Nov 10, 2025

Overview * Immunovant ( IMVT ) Q2 net loss misses analyst expectations * Company advances IMVT-1402 trials across multiple indications, contributing to increased R&D expenses * Immunovant ( IMVT ) maintains strong cash position, supporting trials through GD readout in 2027 Outlook * Company plans to report IMVT-1402 trial results in 2026 and 2027 * Current cash supports operations through...

Trading platform eToro beats profit estimates as retail investors ride market boom

Nov 10, 2025

(Reuters) -Stock and crypto trading platform eToro beat estimates for third-quarter profit on Monday as retail investors maintained their buying streak despite bubble worries, sending shares up 8% before the bell. Equities hit record highs in the quarter as steady earnings, softer inflation expectations and optimism around the AI boom encouraged investors to move back into risk assets. The rally...